Q-omics provides the consensus-scored TUBA4A profile across patient tissues and cancer cell-line models. TUBA4A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TUBA4A is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, TUBA4A protein abundance shows 36,853 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, COAD, and GBM as cancer lineages where TUBA4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBA4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBA4A survival associations across molecular data types. TUBA4A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBA4A RNA expression–survival associations across cancer types. High TUBA4A expression shows unfavorable associations in LUAD, MESO, LIHC, LAML and PAAD, but favorable associations in UCS. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for TUBA4A RNA expression.
This table summarizes TUBA4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TUBA4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBA4A shows higher tumor expression in COAD, THCA, LUAD, LIHC, HNSC and PAAD. The COAD box plot shows higher TUBA4A RNA expression in tumor versus normal tissue (log2 FC = +1.416, t-test p < 0.001).
This table shows molecular features associated with TUBA4A in patient tissues and cancer cell lines. In patient samples, TUBA4A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBA4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
